​

Lexicon Pharmaceuticals Stock (NASDAQ:LXRX)

ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.66

52W Range

$0.32 - $1.83

50D Avg

$1.39

200D Avg

$1.22

Market Cap

$728.73M

Avg Vol (3M)

$2.80M

Beta

1.01

Div Yield

-

LXRX Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

103

IPO Date

Apr 07, 2000

Website

LXRX Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24
License$45.00M-
Product$4.65M-
Reportable Segment-$31.08M

Fiscal year ends in Dec 25 | Currency in USD

LXRX Financial Summary

Dec 25Dec 24Dec 23
Revenue$49.80M$31.08M$1.20M
Operating Income$-48.91M$-197.12M$-171.75M
Net Income$-50.34M$-200.40M$-177.12M
EBITDA$-48.91M$-184.29M$-169.76M
Basic EPS$-0.14$-0.63$-0.80
Diluted EPS$-0.14$-0.63$-0.80

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 05, 26 | 8:30 AM
Q3 25Nov 06, 25 | 8:30 AM
Q2 25Aug 06, 25 | 8:30 AM

Peer Comparison

TickerCompany
GOSSGossamer Bio, Inc.
FULCFulcrum Therapeutics, Inc.
CMPXCompass Therapeutics, Inc.
FDMT4D Molecular Therapeutics, Inc.
BCYCBicycle Therapeutics plc
ADCTADC Therapeutics S.A.
OMEROmeros Corporation
NMRANeumora Therapeutics, Inc. Common Stock
RAPTRAPT Therapeutics, Inc.
OCGNOcugen, Inc.